Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

By Anders Göransson

May 8, 2024 10:06 AM

Ono pays 2.4 billion dollars to take over all shares in the Massachusetts-based company in a deal that is expected to be completed during the third quarter of the year.

With the purchase, Ono acquires the already approved cancer drug Qinlock, a kinase inhibitor for the treatment of gastrointestinal stromal cell tumor (GIST), and vimseltinib, which is a drug candidate under evaluation in phase III as a treatment for tenosynovial giant cell tumor (TGCT).

– We expect that this acquisition of Deciphera will not only expand Ono's target oncology portfolio, but also accelerate Ono's business development in the United States and Europe, and strengthen kinase drug discovery research, Ono Chief Executive Officer Gyo Sagara said in a statement.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.